Invasive Candidiases Clinical Trial
Official title:
ECMM Candida Registry - CandiReg
The objective of the European Confederation of Medical Mycology - ECMM Candida Registry (CandiReg) is to overcome the lack of knowledge on epidemiology, clinical course, and molecular characteristics of invasive infections due to invasive Candida infections and to function as a platform for future studies and in case of outbreaks.
The specific objectives are: To describe the global incidence of invasive Candida infection To monitor trends globally and locally over time To define patient risk groups To assess antifungal resistance among Candida spp. causing invasive diseases worldwide To assess attributable mortality of invasive Candida infection To assess incremental costs associated with invasive Candida infection To describe the clinical pattern of disease To document diagnostic procedures performed for confirmation of diagnosis To describe first-line and salvage treatment regimens applied, guideline adherence, their efficacy and impact on patient survival To inform consensus guidelines To develop clinical screening and diagnostic procedures Set up of a collection of isolates with molecular characterization and evaluation of resistance genes ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
Completed |
NCT05848492 -
Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.
|
Phase 3 | |
Completed |
NCT03468803 -
Influence of Open and Laparoscopic Abdominal Surgery Involving the Intestinal Tract on Serum 1,3-ß-D-Glucan (BDG) Values
|
N/A | |
Recruiting |
NCT03090334 -
A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis
|
N/A | |
Completed |
NCT04148287 -
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
|
Phase 2 | |
Recruiting |
NCT03717623 -
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
|
Phase 4 |